Agilent Technologies, Inc. (A) Deep Value Intelligence Report

Intelligence Summary#

Thesis + Conditions#

Core Thesis: EXECUTIVE SUMMARY Agilent (A) is an elite, wide-moat compounder generating 16.2% ROIC and 52.4% gross margins. However, at $143 (28.6x P/E), the stock is priced for flawless macroeconomic execution, leaving a razor-thin margin of safety.

Key Risks: - Agilent (A) is an elite, wide-moat compounder generating 16.2% ROIC and 52.4% gross margins. However, at $143 (28.6x P/E), the stock is priced for flawless macroeconomic execution, leaving a razor-thin margin of safety. Under our Value Investing Framework, the primary risk here is not business impairment, but overpaying. The easy tactical rebound from recent lows has fully played out. We are shifting to a tiered-entry strategy: maintaining a highly constructive WATCH to capitalize on a modest multiple contraction (target ~24-25x P/E) without demanding a deep-value discount that elite franchises rarely offer. - Risky Analyst (The Moat Focus): Agilent is a "technological toll booth." High regulatory switching costs protect its consumables/software ecosystem. Valuation fears cause investors to miss out on compounding machines. China changes are a strategic pivot to higher-margin, high-end segments. - Safe Analyst (The Valuation/Risk Focus): A 28.6x P/E (3.5% earnings yield) offers no margin of safety against Treasuries. If growth slows, a multiple contraction to 20x risks a 30% capital drawdown. Losing mid-market volume in China threatens the economies of scale needed to fund R&D. Buybacks at 29x are value-destructive.

Confidence: Medium

Analyst Team Reports#

Fundamentals Analysis#

Latest Earnings Snapshot#

Most recent reported quarter anchored on 2026 Q3, with prior-year comparison when available.

Key Takeaways: This snapshot anchors the most recent reported quarter before the narrative analysis. It helps readers separate long-run business quality from whatever changed in the latest earnings print.

17-Year Financial Metrics for A#

All values below are computed deterministically from raw data - not estimated by AI.

Issuer profile: operating company (Healthcare / Diagnostics & Research).

17-Year Financial Metrics#

Annual rows come from reported financial statements. The final TTM row is computed from the latest four quarters.

Profitability Metrics#

• Return on Equity (ROE): 19.3%
• Return on Invested Capital (ROIC): 16.2%
• Return on Assets (ROA): 10.2%
• Gross Margin: 52.4%
• Operating Margin: 21.3%
• Net Profit Margin: 18.8%

Liquidity Metrics#

• Current Ratio: 1.96
• Quick Ratio: 1.40

Leverage Metrics#

• Debt-to-Equity Ratio: 0.50
• Interest Coverage Ratio: 13.21
• Net Debt: $1.56B

Growth Metrics (Year-over-Year)#

• Revenue Growth: 6.7%
• Net Income Growth: 1.1%
• Free Cash Flow Growth: -16.1%
• Revenue CAGR (3-Year): 0.5%
• Revenue CAGR (5-Year): 5.4%

Valuation Metrics#

• P/E Ratio (TTM): 28.57
• Forward P/E: 21.18
• Price-to-Book: 5.48
• Price-to-Sales: 5.47
• PEG Ratio: 1.20
• EV/EBITDA: 20.55
• Free Cash Flow Yield: 2.9%
• Earnings Yield: 3.5%

Owner Earnings (Buffett Method, Code-Computed)#

• Net Income: $1.30B
• • Depreciation & Amortization: $288.0M
• • Capital Expenditures: $-407.0M
• • Working Capital Changes: $-131.0M
• = Owner Earnings: $1.43B

Intrinsic Value (Code-Computed)#

• Current Price: $143
• Headline Intrinsic Value (business-model routed): $66 Business model: operating company - weighted blend [Damodaran FCFF + reverse-DCF fair + owner-earnings DCF] (operating_company) Model spread (min-max across DCFs): $40 - $89 Margin of safety vs. price (headline): -117.3% Routing note: General operating company: balanced blend of Damodaran FCFF and the owner-earnings DCF with a reverse-DCF sanity check.
• Buffett Method (Owner Earnings): Conservative: $15 Average: $89 Optimistic: $293
• Cash Flow Method (FCF): Conservative: $31 Average: $70 Optimistic: $280
• Damodaran FCFF (WACC + margins + reinvestment): Conservative: $30 Average: $40 Optimistic: $58 Monte Carlo band (P10-P90): $31 - $54 (median $41) P(intrinsic value > price): 0.0%
• Reverse-DCF: price implies ~19.0%/yr owner-earnings growth for 10y; trailing 3y was -6.6%, 5y 19.0%.

Piotroski F-Score: 5/9#

• Positive Net Income: PASS
• Positive Operating Cash Flow: PASS
• ROA Improvement: FAIL
• Cash Flow > Net Income: PASS
• Decreasing Debt: PASS
• Improving Current Ratio: FAIL
• No Dilution: PASS
• Improving Gross Margin: FAIL
• Improving Asset Turnover: FAIL

ANALYST STANCE: WATCH

Agilent Technologies Inc. (A) - Buffett-Style Fundamental Analysis#

Agilent is a high-quality healthcare tools, diagnostics, and life-science instrumentation company with durable customer relationships, strong gross margins, recurring service revenue, and solid returns on capital. The business looks fundamentally healthy, but the stock price embeds a demanding growth expectation. At $143 per share, the deterministic model's headline intrinsic value is $66, with a model spread of roughly $40-$89 across more robust DCF approaches, implying the current price is well above conservative cash-flow value.

---

Current vs. 10-Year Historical Average Comparison#

10-year averages below use the last 10 completed fiscal years, 2016-2025. "Current" uses the latest 2026 TTM row from the deterministic dataset.

Key Takeaways: Agilent's profitability, margins, revenue, earnings, and free cash flow are all above their 10-year averages, confirming that this is a high-quality operating business. The concern is valuation: the market price and market cap are also well above historical norms, while recent growth is only moderately above average. The stock is not obviously overextended versus its own historical P/E, but cash-flow valuation suggests the current price already discounts a very optimistic future.

---

Market Metrics Interpretation#

Agilent's market price of $143 and market cap of $40.50B reflect a premium-quality healthcare tools franchise. The market is valuing the company as a durable compounder, not as a cyclical industrial or commodity business.

The P/E ratio of 28.17x is lower than the 10-year average of 35.64x, but that historical average is inflated by unusual years when earnings were temporarily depressed. On a Buffett-style basis, a 28x earnings multiple requires confidence in sustained high returns, predictable growth, and long-duration competitive advantage. At an earnings yield of roughly 3.5%, the stock offers little immediate valuation protection.

The P/B ratio of 5.50x is slightly below the 10-year average of 5.88x. The deterministic issuer profile classifies Agilent as an operating healthcare diagnostics and research company, and P/B is not explicitly marked "Not meaningful." Still, for an IP-heavy science tools business with intangible know-how, customer relationships, installed instruments, and recurring service revenue, book value does not fully represent economic value. Therefore, P/B should be treated as secondary; intrinsic value should be anchored primarily on owner earnings and free cash flow.

---

Profitability and Business Quality#

Agilent's profitability profile is strong. Gross margin is 53.8% TTM, slightly above the long-run level and consistent with a differentiated products and services business. Operating margin of 22.2% is well above the 10-year average of 19.4%, showing that the business has scaled efficiently and preserved pricing power.

ROE of 19.6% is above the decade average, while ROIC of 14.9% remains healthy but below the 10-year average of 16.3%. For Buffett-style analysis, ROIC is especially important because it measures how efficiently the company converts reinvested capital into operating profit. Agilent clears a quality threshold, but the downward drift from the 2021-2022 peak suggests that future compounding may be solid rather than extraordinary.

Net margin has improved to 19.5%, versus a 10-year average of 16.1%. This supports the argument that Agilent has a real economic moat: technical differentiation, high switching costs, regulated customer workflows, service attachment, and recurring aftermarket revenue.

---

Growth Analysis#

Agilent's TTM revenue growth of 6.1% is slightly above the 10-year average of 5.8%, but the decade includes periods of volatility. Revenue declined in 2024, recovered in 2025, and continued improving on a TTM basis. The company is growing, but not at the kind of sustained double-digit rate that would naturally justify a very high valuation.

Net income growth of 10.5% TTM is encouraging, but the 10-year average of 29.1% is not a clean benchmark because it is distorted by rebound years from depressed earnings. A more realistic normalized view is that Agilent is capable of mid-single-digit to low-double-digit earnings growth when end markets are healthy.

Free cash flow growth of 10.0% TTM is positive after a -16.1% fiscal-year decline in 2025. This matters because Buffett-style valuation depends more on owner earnings durability than accounting earnings alone. The current free cash flow recovery is encouraging, but the long-term investment case still requires consistent cash compounding.

---

Balance Sheet and Financial Strength#

Agilent has a sound but not debt-free balance sheet. Total debt is $3.95B, above the 10-year average of $2.55B, while cash and equivalents are $1.76B, roughly in line with the historical average. Net debt is approximately $1.56B, which is manageable given TTM owner earnings of $1.43B and operating cash flow of $1.61B.

The debt-to-equity ratio of 0.54x is slightly above the 10-year average of 0.48x, but still reasonable. Interest coverage of 13.21x indicates no near-term solvency stress. Buffett would likely view the balance sheet as acceptable, though not a source of major hidden value.

The current ratio of 1.96 and quick ratio of 1.40 suggest adequate liquidity. These ratios are meaningful for this operating company, but they are not the central valuation driver. The central question is whether Agilent can compound owner earnings fast enough to justify the current price.

---

Cash Flow and Capital Allocation#

TTM free cash flow is $1.27B, above the 10-year average of $1.03B. However, the current FCF yield is only about 2.9%, which is low for a value investor. A low FCF yield can be acceptable for a truly exceptional compounder, but it leaves little margin of safety if growth disappoints.

Agilent now pays $1.01 per share in dividends, compared with no dividends for much of the historical period. This indicates a more mature capital return policy. The dividend is modest and appears well covered, but the company's value creation will still depend more on reinvestment returns, buybacks, acquisitions, and operating cash flow growth than on dividend income.

Piotroski F-Score is 5/9, which is neutral. Positives include profitability, positive operating cash flow, cash flow exceeding net income, lower debt, and no dilution. Weaknesses include declining ROA, weaker current ratio, weaker gross margin versus the prior period, and lower asset turnover. That combination supports a "good business, but watch the trend" conclusion.

---

Revenue Breakdown#

Most recent revenue mix is estimated by major operating segment and reconciled to deterministic FY2025 revenue of $6.95B. Agilent reports through three major business groups: Life Sciences and Applied Markets, Agilent CrossLab, and Diagnostics and Genomics.

Key Takeaways: Agilent's revenue is diversified across instruments, consumables, diagnostics, genomics, and services. The CrossLab service business is especially valuable because it tends to be recurring and tied to the installed base. The mix supports a durable moat, but roughly half the business remains exposed to instrument and capital-spending cycles.

---

Buffett-Style Owner Earnings DCF Valuation#

The deterministic dataset calculates Buffett-style owner earnings as follows:

Key Takeaways: Agilent converts accounting earnings into substantial owner earnings, which is a major quality signal. Owner earnings of $1.43B are close to TTM net income and free cash flow, suggesting earnings quality is reasonably strong. The issue is not cash generation; the issue is whether that cash generation is worth the current market capitalization.

Assumptions for the hand-built DCF sanity check:

Key Takeaways: The DCF uses a Buffett-style 10% required return and a conservative terminal growth rate. The share count is estimated from the deterministic market cap and share price. Net debt is subtracted to avoid overstating equity value.

Key Takeaways: Even under an optimistic but fading growth case, the hand DCF produces a value meaningfully below the current price. The conservative case lands very close to the deterministic model's headline intrinsic value of $66. This supports the conclusion that the market price requires either a much longer runway of high growth, a lower required return, or materially better future margins than currently modeled.

DCF formula used:

Key Takeaways: The valuation is highly sensitive to growth assumptions because much of the value comes from the terminal value. That is normal for a durable company, but it also means the investment case depends heavily on sustained compounding. If growth merely normalizes around mid-single digits, the current stock price offers little downside protection.

The deterministic intrinsic value model provides the following additional valuation anchors:

Key Takeaways: The stronger model-based valuation anchor is the routed intrinsic value of $66, with core DCF support mostly between $40 and $89. The reverse DCF is the key warning: the current price implies roughly 19% annual owner-earnings growth for 10 years, which is aggressive compared with Agilent's recent growth record. The very high optimistic owner-earnings DCF outcome requires unusually strong and sustained compounding, not merely normal execution.

---

Warren Buffett-Style Qualitative Assessment#

Key Takeaways: Agilent looks like a business Buffett would respect but not necessarily buy at today's price. The company has many traits of a durable compounder, including high margins, good returns on capital, and recurring revenue. However, Buffett's discipline is to buy wonderful businesses at sensible prices, and the current price does not appear sensible relative to owner earnings.

---

Key Investment Insights#

Agilent's strongest investment attributes are its durable end markets, technical differentiation, high gross margins, and recurring service revenue. The installed base creates customer stickiness, and regulated scientific workflows make customers less likely to switch providers purely on price.

The business has become more profitable over time. Operating margin has risen meaningfully above the decade average, and net margin is near 20%. That suggests management has executed well and the company has real pricing power.

However, valuation is the central problem. A 28x TTM P/E, 5.47x price-to-sales, 20.55x EV/EBITDA, and 2.9% FCF yield leave limited room for disappointment. The reverse DCF implies approximately 19% annual owner-earnings growth for 10 years, which appears ambitious given recent revenue growth around 6% and fiscal 2025 FCF contraction.

---

Red Flags and Risks#

Key Takeaways: The largest risk is not business failure; it is overpaying for a good business. Agilent's fundamentals are strong enough to keep it on a quality watchlist, but the valuation assumes a very favorable future. If growth slows or margins normalize, the share price could re-rate lower.

---

Opportunities#

Key Takeaways: Agilent has attractive long-term opportunities, especially in recurring services, diagnostics, genomics, and biopharma workflows. If management can sustain high margins while returning to faster organic growth, intrinsic value could compound. The challenge is that much of this upside already appears priced into the stock.

---

Final Investment Stance: WATCH#

Agilent is a high-quality company with a credible moat, strong margins, healthy returns on capital, manageable leverage, and durable long-term end markets. From a Buffett perspective, the business quality is clearly above average.

However, the stock does not currently offer a sufficient margin of safety. The deterministic headline intrinsic value is $66, while the current price is $143. Even an optimistic hand-built owner-earnings DCF produces a value around $100 per share, still below the market price. The reverse DCF requires roughly 19% annual owner-earnings growth for 10 years, which is a high bar for a company currently growing revenue around the mid-single digits.

This is a WATCH, not an AVOID, because the business is strong and could become attractive at a lower valuation. A more compelling Buffett-style entry point would likely require either a significant pullback toward intrinsic value, evidence of sustained double-digit organic growth, or a material upward reset in durable free cash flow.

Key Takeaways: Agilent is a fundamentally attractive company, but the stock price is too demanding for a Buffett-style value purchase today. The business deserves monitoring because it has durable competitive advantages and strong cash generation. At the current price, investors are paying for excellence in advance, leaving little protection if growth or margins disappoint.

Fundamental Visuals#

This graph tracks the profitability and return metrics (ROE, ROIC, Margins) of A over the past decade, highlighting capital efficiency trends.

This chart illustrates the financial health of A over the last 10 years, mapping cash equivalents and free cash flow against total obligations (Debt).

This breakdown chart from Revenue Breakdown shows the proportional composition for A - useful for understanding what drives or risks the business.

---

Intrinsic Value Analysis (Buffett)#

Following Warren Buffett's value investing philosophy: Circle of Competence, Economic Moat, Management Quality, and Margin of Safety.

Intrinsic Value Snapshot#

Price is what you pay. Intrinsic value is what the business may be worth based on the cash it can create for owners over time. We show a range, not one magic number.

• Current Price: $143.12
• Value Range (conservative to optimistic across both DCF methods): $28.45 to $101.86

Owner Earnings (Buffett Method)

• Net Income: $1,303,000,000.00
• Depreciation & Amortization: $288,000,000.00
• Capital Expenditures: $-407,000,000.00
• Working Capital Changes: $-131,000,000.00
• Owner Earnings: $1,434,000,000.00

Intrinsic Value

Buffett Method

Uses owner earnings. Stricter, and usually more conservative. - Conservative: $32.19 - Average: $51.76 - Optimistic: $80.18 - Discount Rate: 10.0%

Cash Flow Method

Uses free cash flow. Better for companies spending heavily today to grow tomorrow. - Conservative: $28.45 - Average: $57.16 - Optimistic: $101.86 - Discount Rate: 10.0%

ANALYST STANCE: AVOID

Agilent Technologies Inc. - Buffett-Style Investment Review#

Agilent is a high-quality life sciences, diagnostics, and analytical instruments company with respectable margins, recurring consumables/service revenue, and meaningful switching costs from installed instruments and regulated customer workflows. The business is understandable and economically decent. The stock, however, is priced as if Agilent can compound at a rate far above its recent fundamentals, and the current margin of safety is deeply negative.

---

1. Factor Scorecard#

Key Takeaways: Agilent passes the basic business-quality test: it is profitable, understandable, and has real customer stickiness. The problem is not solvency or business fragility. The problem is that today's stock price already capitalizes a much better future than the recent financial record supports.

---

2. Moat Analysis#

Key Takeaways: Agilent's moat is built more on trust, switching friction, consumables attachment, and technical credibility than on network effects. That is a respectable moat, but it does not justify paying any price. The moat is real, but not dominant enough to overcome the current valuation gap.

---

3. Management Quality Assessment#

Key Takeaways: Management appears capable and conventional, but this is not a Berkshire-style owner-operator story. The company has made rational reinvestment decisions, yet the investment case depends more on business quality and valuation than on extraordinary capital allocation.

---

4. Financial Summary Table#

Key Takeaways: Agilent's profitability metrics are good, especially the 52.4% gross margin and 19.3% ROE. But the valuation metrics are poor: a 2.9% free-cash-flow yield and 28.6x earnings leave little room for disappointment. The reverse-DCF is the clearest warning sign, because the stock price implies roughly 19% annual growth for a decade.

---

5. Owner Earnings Calculation#

Using the owner-earnings DCF value from the valuation pack:

Key Takeaways: Agilent generates real owner earnings, but the current price asks investors to accept a low earnings yield. At roughly 27.6 times estimated owner earnings, the stock offers little immediate cash-return protection. For a Buffett-style buyer, that means future growth must do nearly all the work.

---

6. Three-Scenario DCF Valuation#

Key Takeaways: Even under a conservative growth scenario, Agilent's intrinsic value estimate remains far below the current price. The stock is not merely a little expensive; it is priced at a major premium to cash-flow-based value. A Buffett investor would require either a much lower price or much stronger evidence of durable high-teens compounding.

---

7. Margin of Safety Analysis#

Key Takeaways: Agilent is a good business at a bad price. The market appears to be pricing the company like a high-growth compounder, while the recent growth profile looks much more moderate. The gap between price and intrinsic value is too large to ignore.

---

8. Final Buffett Scorecard#

Key Takeaways: The final score is pulled down overwhelmingly by valuation. Agilent earns respectable marks for moat, profitability, balance sheet, and business quality, but the current stock price overwhelms those positives. This is a classic case where a good company does not equal a good investment.

---

9. Investment Stance#

Agilent belongs on a quality watchlist, not in a Buffett-style portfolio at today's price. A more attractive entry point would require a material decline toward cash-flow-based intrinsic value, or a fundamental acceleration strong enough to make the current reverse-DCF assumptions credible. At $143, the investor is paying for a wonderful future before it has been earned.

Valuation Bridge#

This bridge places the current market price beside each intrinsic value lens so readers can see whether upside depends on one method or shows up across several methods.

Key Takeaways#

If one method is far above the others, the upside case depends on a specific modelling assumption. When several methods cluster together, the valuation story is more robust.

Valuation Visuals#

This comparison chart from Latest Earnings Snapshot stacks current figures against historical benchmarks for A, making it easy to see where the company trades relative to its own averages.

This comparison chart from Current vs. 10-Year Historical Average Comparison stacks current figures against historical benchmarks for A, making it easy to see where the company trades relative to its own averages.

This comparison chart from Buffett-Style Owner Earnings DCF Valuation stacks current figures against historical benchmarks for A, making it easy to see where the company trades relative to its own averages.

This comparison chart from Buffett-Style Owner Earnings DCF Valuation stacks current figures against historical benchmarks for A, making it easy to see where the company trades relative to its own averages.

This comparison chart from Buffett-Style Owner Earnings DCF Valuation stacks current figures against historical benchmarks for A, making it easy to see where the company trades relative to its own averages.

---

Trend & Growth Analysis (Lynch/Druckenmiller/Fisher)#

Following Peter Lynch's GARP, Stanley Druckenmiller's macro-aware approach, and Philip Fisher's scuttlebutt methodology.

ANALYST STANCE: AVOID

Agilent Technologies "A" - Growth Investor Report#

Agilent is a high-quality life-sciences and analytical-instruments company, but it does not currently fit a Lynch / Druckenmiller / Fisher-style fast-growth setup. The company looks more like a stalwart / stable cash cow than a ten-bagger candidate: revenue growth is modest, valuation is demanding, and the current price appears to require a major growth acceleration that is not yet visible in the fundamentals.

---

1. Lynch Classification#

Key Takeaways: Agilent is a strong and profitable company, but its current growth profile is not that of a classic Lynch fast grower. With revenue growing around 7% and the stock trading near 29 times earnings, the valuation already prices in a much stronger future than the company is currently demonstrating.

---

2. The Story in 3 Bullets#

• Agilent sells the "picks and shovels" of science: instruments, consumables, software, and services used by pharma, biotech, chemical, diagnostics, and academic labs.
• The business benefits from durable demand: drug discovery, biologics, precision medicine, environmental testing, and clinical research all require increasingly sophisticated lab infrastructure.
• The challenge is growth velocity: this is a high-quality compounder, but current growth is too slow to support a ten-bagger case from today's valuation without a major inflection.

---

3. TAM Analysis and 10x Test#

Key Takeaways: Agilent operates in attractive scientific end markets, but the company is already large. A 10x revenue outcome would require it to become a much bigger share-taker across multiple lab and life-sciences categories, not just benefit from normal market growth.

---

4. Revenue Growth Trend#

Key Takeaways: The most important issue is that Agilent's revenue growth is not accelerating. For a Druckenmiller-style growth setup, we would want to see growth moving from 6% to 10% to 15% or higher; instead, the current evidence points to a stable but slower compounder.

---

5. Unit Economics#

Key Takeaways: Agilent's unit economics cannot be evaluated like a SaaS company, but its gross margin and balance-sheet liquidity are healthy. The business appears financially sound; the issue is not survivability, but whether the company can grow fast enough to justify the current valuation.

---

6. Inflection Point Assessment#

Key Takeaways: Agilent has exposure to good scientific megatrends, but exposure alone is not an inflection point. The data does not yet show accelerating revenue, accelerating margins, or a sudden competitive opening that would support aggressive growth underwriting.

---

7. Macro Setup Evaluation#

Key Takeaways: The macro environment is not hostile to Agilent, and the company sits in durable scientific end markets. However, the macro setup is not powerful enough to turn a 6-7% grower at nearly 29 times earnings into an obvious growth bargain.

---

8. Fisher 15 Points Score#

Key Takeaways: Fisher would likely appreciate Agilent's product quality, customer relationships, and recurring workflow position. But the score is capped by the lack of visible high-growth acceleration and the limited evidence that margins or market share are entering a new phase.

---

9. Valuation Analysis#

Key Takeaways: The valuation is the core problem. Agilent's price appears to require a long period of growth far above what the company is currently producing, which creates a poor risk-reward setup for a growth investor looking for mispriced acceleration.

---

10. Scenario Valuation#

Key Takeaways: The base case does not look broken, but it also does not look compelling. To justify a strong growth-investor buy, Agilent would need to show a bull-case revenue acceleration that is not yet visible in the current numbers.

---

11. Growth Investor Scorecard#

Key Takeaways: Agilent scores well on quality, profitability, and market durability, but weakly on revenue acceleration and valuation. The total score lands in watch-list territory mathematically, but for new growth capital the stance is more conservative because the valuation gap is large.

---

12. Position Size Stance#

Key Takeaways: Agilent may be acceptable for investors who already own it and value stability, but it is not attractive enough for new growth-oriented capital at the current price. A disciplined investor should wait for either a valuation reset or a visible revenue inflection.

---

Key Risks and Catalysts#

Key Takeaways: The upside case depends on a recovery in lab spending, stronger biopharma demand, and better execution in high-growth scientific workflows. The downside risk is that Agilent remains a solid but slow grower while the market continues to value it like a faster one.

---

Final View#

Agilent is a quality company, not a quality growth-stock setup at this price. It has durable markets, strong margins, and a credible scientific franchise, but the current evidence points to a stalwart, not a fast grower. For Lynch-style GARP, the PEG is too high; for Druckenmiller-style inflection investing, the acceleration is not proven; and for Fisher-style long-term compounding, the business quality is good but not enough to overcome valuation risk.

Decision: AVOID for new growth capital; monitor for a pullback or confirmed revenue acceleration.

---

Market Technical Analysis#

ANALYST STANCE: WATCH

Agilent Technologies Inc. - Technical Analysis for Ticker A#

Data is available through 2026-09-10. The latest close is $143.12, while the current date is 2026-09-11. Agilent is in a longer-term recovery structure, but the short-term tape has deteriorated meaningfully after an August momentum peak.

Key Takeaways: The selected indicators are deliberately balanced across trend, momentum, volatility, and volume confirmation. The main message is that Agilent's long-term trend remains constructive, but short-term and volume-adjusted momentum have turned negative. The stock is now testing an important medium-term support area near the 50-day moving average.

Price Structure and Trend#

Agilent staged a strong recovery from the spring and early-summer base, especially after the sharp late-May upside gap from the mid-$110s into the mid-$130s. That move changed the character of the chart from a broken downtrend into a recovery phase. The stock then consolidated through June and July before pushing into a strong August rally.

The most recent high-quality upside phase peaked in late August. The stock closed at $159.00 on 2026-08-21, then reached an intraday high of $163.75 on 2026-08-27, but failed to sustain that breakout area. Since then, price has rolled over to $143.12, a decline of roughly 10% from the $159 close and more than 12% from the $163.75 intraday high.

The most important current level is the 50-day SMA at $142.99. The latest close of $143.12 is only slightly above that level, meaning the stock is sitting directly on medium-term support. A decisive close below the 50-day average would weaken the recovery structure and could shift attention toward lower support zones in the high-$130s and mid-$130s.

Moving Average Read#

The moving-average stack is still broadly constructive on a longer-term basis: the 10 EMA is above the 50 SMA, and the 50 SMA is above the 200 SMA. That alignment usually reflects an established recovery or uptrend. However, price has slipped below the 10 EMA, and the 10 EMA itself has turned down from roughly $153.70 in late August to $148.66 now.

This means the stock has transitioned from an upside momentum trend into a pullback phase. The 50-day SMA is still rising, from about $134.79 on 2026-08-11 to $142.99 on 2026-09-10, which is constructive. But price must hold near this area soon; otherwise, the rising 50-day average may stop acting as support and become resistance.

The 200-day SMA near $131.25 is still far below price. That gives the broader trend some cushion. Unless Agilent breaks significantly below the 50-day and begins trending toward the 200-day, the larger recovery remains intact.

Momentum: MACD and RSI#

Momentum has weakened sharply. The MACD peaked above 5.3 around late August and has dropped to 0.83. It is still above zero, so the broader momentum regime has not fully flipped bearish, but the rate of decline is notable.

The MACD histogram is more concerning. It moved from positive territory in mid-to-late August to -1.83 by 2026-09-10. That signals that the MACD line is below its signal line and that downside momentum is accelerating. This is often an early warning that a pullback may not be finished yet.

RSI tells a similar story. It was deeply overbought in August, reaching above 80 on 2026-08-21. It has now fallen to 40.66, which is not oversold but is clearly below the neutral 50 zone. This suggests selling pressure is active but not yet washed out. For a bullish reversal setup, traders would likely want to see RSI stabilize above 40 and reclaim 50, rather than continue sliding toward 30.

Volume and Volatility Conditions#

The VWMA is $152.65, well above the latest close of $143.12. This is a negative short-term volume signal. It implies that the average price adjusted for volume remains meaningfully higher than the current price, so recent trading has not yet shown convincing volume-backed accumulation near the lows.

The ATR is $4.36, which is elevated compared with mid-August readings near the low-to-mid $3 range. This means daily movement remains wide. Traders should be careful about using tight stops around the current 50-day SMA area, because normal volatility alone could produce temporary undercuts. A more practical approach would be to judge whether price can reclaim key levels such as the 10 EMA, rather than reacting to one minor intraday break.

Trading Interpretation#

Agilent is not in a clean buy setup at the moment. The longer-term trend is still constructive because price remains above the 200-day SMA and the 50-day SMA is rising. However, the short-term trend has clearly weakened: price is below the 10 EMA, below VWMA, MACD momentum is deteriorating, and RSI is below 50.

For bullish traders, the key question is whether the $143 area becomes a successful support test. A constructive signal would be a stabilization above the 50-day SMA followed by a move back above $148.50-$149.00, which would reclaim the 10 EMA area. A stronger confirmation would be a recovery through $152.50-$153.00, near the VWMA, because that would show that price is regaining volume-weighted trend support.

For bearish or cautious traders, a close below the 50-day SMA, especially if accompanied by continued negative MACD histogram readings and RSI slipping toward the mid-30s, would suggest the pullback is extending. In that case, the next zones to monitor would likely be the prior consolidation area around the high-$130s, then the mid-$130s. The 200-day SMA around $131.25 remains the larger line separating a normal pullback from a deeper trend reset.

Bottom Line#

The technical stance is WATCH, not ADVOCATE, because the stock is testing support while short-term momentum is negative. It is also not a full AVOID, because the longer-term trend remains intact and the price is still above both the 50-day and 200-day moving averages. The best setup would be either a confirmed rebound from the 50-day SMA or a cleaner reset closer to stronger support.

Key Takeaways: Agilent is sitting at a critical support test near its 50-day moving average. The broader uptrend is still alive, but short-term momentum and volume-adjusted price action are weak. A recovery above the 10 EMA would improve the setup, while a decisive break below the 50-day SMA would argue for more caution.

---

Options Market Analysis#

Reading options flow - put/call ratios, IV skew, and unusual activity - to gauge institutional positioning and event-driven risk.

Options Market Positioning Report - A#

As of 2026-09-11

1. Put/Call Ratio Analysis#

Key Takeaways: The near-term put/call open interest ratio is 2.28, far above the historical neutral baseline of roughly 0.7, indicating a clear skew toward downside protection or bearish positioning. The volume ratio of 1.50 also leans put-heavy, suggesting current trading activity is reinforcing the defensive tone. However, total open interest is very low, so confidence in the signal should be reduced.

The strongest bearish concentration is in the 2026-09-18 expiration, where put open interest is more than 4 times call open interest. The November chain is less bearish on open interest, but put volume still exceeds call volume, keeping the overall read defensive.

---

2. Implied Volatility Assessment#

Key Takeaways: Reported ATM implied volatility is extremely low across the chain, which may reflect stale or thinly traded options data rather than a strong market view. The available data shows ATM call IV above ATM put IV, which is not consistent with a classic downside-fear put skew. Because OTM put and OTM call IV data was not available, the skew read is limited.

There is no clear evidence from the options data of an elevated IV event premium ahead of a major catalyst. In fact, the unusually low IV readings suggest either very low expected movement or unreliable pricing due to poor liquidity.

---

3. Unusual Options Activity#

Key Takeaways: No near-term contracts met the unusual activity threshold of volume greater than 5x open interest. That means there is no strong evidence of fresh institutional directional bets from the available contract-level data. The put-heavy volume is notable, but without specific high-volume-versus-OI contracts, it is better interpreted as broad defensive activity rather than a confirmed smart-money sweep.

The October expiration is worth monitoring because volume appeared despite very little reported open interest, but the tool did not identify any specific contract as unusual. This reduces conviction in any aggressive directional conclusion.

---

4. Open Interest Concentration and Pinning Risk#

Key Takeaways: The largest expiration-level open interest concentration is in September 18 puts, making that the most important near-term options cluster. However, strike-level open interest was not provided, so precise max-pain, pinning, or gamma-wall levels cannot be identified. Given the low total OI, any pinning effect is likely modest unless concentrated at a specific strike.

The lack of strike-level data means we cannot confidently identify the price levels where dealer hedging could amplify or dampen movement. The broad message is still defensive, but not strong enough to define a clear gamma-driven trading level.

---

5. Overall Options Sentiment Signal#

Key Takeaways: The overall options sentiment for A is BEARISH, mainly because put open interest and put volume are both meaningfully elevated versus calls. That said, the signal is low confidence because the options market appears thin, with no confirmed unusual activity and very low reported IV. This looks more like cautious hedging or bearish protection than a high-conviction institutional downside bet.

Final Summary Table#

Key Takeaways: The options market is leaning bearish for A, driven by a high put/call ratio in both open interest and volume. However, the absence of unusual options activity and the very low liquidity mean this should be treated as a cautious sentiment signal, not a standalone trading trigger. Options data here is best used as a supplemental warning that traders are positioned defensively.

Research Team Commentary#

The Research Manager synthesizes the Bull vs Bear debate into action-free commentary. This is a pre-risk view, not the final stance.

Team, this is exactly the kind of debate we need when looking at high quality compounders. Both the bull and the bear have clearly laid out the fundamental tension with Agilent. It is a wonderful business, but the stock is currently demanding a premium price tag.

Looking at the bull case, the arguments for Agilent's business quality are rock solid. You do not consistently generate a 16.2 percent return on invested capital and 52.4 percent gross margins without a durable economic moat. Agilent's transition to a more recurring revenue model through consumables, software like OpenLab, and services creates immense switching costs. Once a lab is validated on Agilent workflows, swapping them out is a regulatory and operational nightmare. The bull is absolutely right that we cannot ignore the strength of this ecosystem.

On the other hand, the bear makes a mathematically unassailable point about valuation. At nearly 29 times earnings, the stock is priced as if it will compound at double digits for the foreseeable future. If Agilent is only going to grow organically in the mid single digits, paying this much leaves zero margin of safety. If the market eventually decides this is a mature 18 times earnings business, the multiple contraction will wipe out years of underlying fundamental growth. The bear is also right to flag the China substitution risks and the normalization of the biopharma funding cycle.

This brings me to my own past mistakes with this exact stock, which I want to address openly so we do not repeat them. Previously, when Agilent was trading significantly lower after a major drawdown, I looked at the valuation, decided it was not cheap enough for a classic Buffett entry, and slapped a cautious watch on it. By doing so, I completely missed a massive tactical rally up to where it sits today at 143 dollars.

My error then was a classic time horizon mismatch. I used a ten year intrinsic value framework to veto a short term tactical setup. I failed to respect that when an elite, high return business undergoes a major price correction, it does not need to become statistically cheap to rally. It just needs to stop getting worse. The market was rewarding the company for simply stabilizing, and I let my rigid valuation models blind me to an obvious technical and fundamental repair phase.

So, where does that leave us today at 143 dollars?

The reality is that the easy tactical rebound I missed has now largely played out. The stock has re-rated, and we are back to facing the bear's primary concern of valuation. At 29 times earnings, we are no longer in a discounted repair phase. We are paying full retail for a fantastic asset.

Core Takeaway Agilent is an elite, wide moat franchise that has successfully transitioned to an asset light, high return model, but at its current valuation, the margin of safety is razor thin for new long term capital. We should maintain a constructive bias because of the underlying business quality, but we must acknowledge that the recent price action has pulled forward a lot of future returns.

Rationale From a value investing perspective, we want to buy wonderful businesses at fair prices. Today, Agilent is a wonderful business at a full price. The 16 percent ROIC and sticky customer base provide a massive floor under the business, preventing catastrophic fundamental downside. However, the current multiple requires a near flawless macroeconomic backdrop, including a swift recovery in biopharma funding and resilience in China, to justify further outsized gains in the near term. The tactical momentum has been great, but the long term math is getting tight.

Monitoring Plan Over the next one to four quarters, we need to separate the noise from the fundamental trajectory. First, watch the biopharma end market commentary closely. We need to see if funding is actually reaccelerating or just stabilizing. Second, monitor the recurring revenue segments, specifically consumables and services. If those show weakness, the high multiple is at serious risk. Third, keep an eye on capital allocation. The bear made a great point about buybacks at 29 times earnings being potentially value destructive. If management aggressively buys back stock at these levels while organic growth slows, that is a red flag for their capital discipline.

Given that the technical repair I previously missed has now fully materialized in the price, leaving us with a premium valuation, my stance is a watch. However, unlike my past mistake, this is a highly constructive watch. If the stock pulls back to key technical support without a structural degradation in the moat, or if growth velocity unexpectedly accelerates to justify the multiple, we will be ready to upgrade this to an active advocate position. Until then, we observe.

WATCH

Value Investing Team Commentary#

The Investor translates the research view into an investment thesis before risk review. This is still not the final stance.

This analysis evaluates Agilent Technologies (A) through the lens of a long-term business owner. We are not looking for a "trade" but for a durable entry point into a franchise that can compound capital for decades.

1. Business Quality and the Economic Moat#

Agilent represents a quintessential "wonderful business." Its 16.2% ROIC and 52.4% gross margins are not accidents; they are the result of a formidable economic moat built on High Switching Costs and Ecosystem Gravity.

In the world of life sciences, Agilent provides the "picks and shovels." Once a pharmaceutical lab validates a drug manufacturing process using Agilent's liquid chromatography or mass spectrometry systems, the cost of switching to a competitor is not just the price of the new machine-it is the astronomical cost of re-validating the entire workflow with regulators (like the FDA). This creates a "razor-blade" model where the "blades" (consumables, software, and services) now represent a significant and growing portion of recurring revenue. We are buying a toll bridge on the path of scientific discovery.

2. Quality-Scaled Margin of Safety & Valuation#

Our framework suggests that a wonderful, wide-moat business warrants a BUY at a 10-15% discount to intrinsic value.

At a current price of $143.12 and a P/E of approximately 28.6x, the market is pricing in a swift and flawless recovery in biopharma spending and a stabilization of the Chinese market. Using a reverse-DCF approach, the current price implies a long-term earnings growth rate that exceeds Agilent's recent historical organic growth.

While I previously missed a tactical entry by being too rigid during a period of distress, a value investor must distinguish between "Repair Phase Pricing" (when the stock was cheaper) and "Expectation Phase Pricing" (where we are now). At 29x earnings, there is no margin of safety. We are paying "full retail" for an elite asset. If the biopharma recovery is slower than expected or if China's domestic substitution accelerates, the multiple contraction risk could significantly outweigh the underlying business growth.

3. Selective Contrarian Thinking: What is the Market Missing?#

The prevailing sentiment is that Agilent is a "safe" play on the inevitable return of lab spending. However, a contrarian view asks: Is the "asset-light" transition enough to offset structural shifts in China?

The market may be underestimating the "China for China" initiative, where domestic competitors are increasingly favored for mid-tier lab equipment. While Agilent is insulated at the high end of the complexity curve, the "middle" of the market-a huge volume driver-is becoming a geopolitical battlefield.

Furthermore, management's capital allocation requires scrutiny. If the company is aggressively repurchasing shares at 29x earnings while organic growth remains in the mid-single digits, they are potentially destroying shareholder value rather than creating it. As owners, we prefer buybacks only when the stock trades below intrinsic value.

4. Management and Capital Allocation#

Agilent's management has done an excellent job shifting toward higher-margin services and software (OpenLab). This improves the quality of earnings. However, our partnership requires them to be disciplined "Value Investors" of their own capital. At today's prices, we would prefer to see that capital deployed into high-ROIC R&D or strategic M&A that expands the moat, rather than high-priced buybacks.

5. Long-Term Perspective#

If we owned 100% of Agilent, we would be very happy with the cash it produces. But as minority shareholders, our entry price determines our internal rate of return (IRR). At $143, the "yield" on our investment (Earnings Yield) is roughly 3.5%. For a business growing organic revenue at 4-6%, the path to a 10% annual return requires significant multiple expansion (unlikely from 29x) or a massive acceleration in growth that is not yet visible in the fundamentals.

Conclusion#

Agilent is a business we want to own, but not at any price. We have missed the "tactical" opportunity to buy the repair, and we must now exercise the discipline to wait for a "wonderful price." We will let the "gin rummy" players trade the short-term noise while we wait for a fumbled hand that offers us a meaningful margin of safety.

ANALYST STANCE: WATCH

Deep Values Commentary#

The Risk Management Team debates and the Risk Judge provides the final action-free verdict. This section determines the final ADVOCATE / WATCH / AVOID stance.

Final Stance Scorecard#

This scorecard converts the final research view into a weighted decision frame. It does not replace the narrative judgement, but it makes the main drivers of the verdict easier to scan.

Key Takeaways#

The weighted score lands at 2.83 / 5.0, while the final stance remains WATCH. This is useful as a quick calibration aid rather than a mechanical signal.

Risk Summary#

Higher scores indicate more risk pressure. The watch threshold is a simple guardrail: above it, the position needs tighter monitoring or a wider margin of safety.

Key Takeaways#

This view helps readers separate where the risk sits: valuation, business quality, balance sheet, or growth durability. It is especially useful when the final stance is close to the line between WATCH and AVOID.